The Tokyo District Court on Thursday, September 17, 2020 delivered a ruling in favor of Daicel Corporation (Head Office: Kita-ku, Osaka, President & CEO: Yoshimi Ogawa, hereinafter: “Daicel”) in a patent infringement case requesting an injunction against Daicel’s product (Heisei 30 (wa) #18555).

The case was filed by Otsuka Pharmaceutical Co., Ltd. (hereinafter: “Otsuka Pharmaceutical”) (Plaintiff, Head Office: Minato-ku, Tokyo, President: Makoto Inoue) in the Tokyo District Court on June 11, 2018, alleging that the production method of Daicel’s Equol “EQ-5” and the products of its customer using the same raw materials, infringe Plaintiff’s Japanese Patent 6275313 and requested an injunction against Daicel and the customer’s products.

On September 17, 2020, the Court rejected Otsuka Pharmaceutical’s claim and ruled that Daicel’s production method does not infringe Otsuka Pharmaceutical’s patent and Daicel thus won the case.

Daicel has long regarded intellectual property rights such as patents as crucial management resources and has closely linked intellectual property with its business and R&D activities. While Daicel respects third party’s valid intellectual property rights, Daicel also asks others to respect Daicel’s intellectual property rights as well. Daicel will protect its products with its own intellectual property rights and take a resolute attitude in handling patent cases. Daicel will continue to maintain a stable supply of products to our customers.

<For Inquiries>
Investor Relations & Corporate Communications
Daicel Corporation
TEL: +81.3.6711.8121